Qualification of Gene and Protein Signatures from CITE-seq Data for Deep Immunophenotyping in Human Clinical Trials

Home > Science Hub > Qualification of Gene and Protein Signatures from CITE-seq Data for Deep Immunophenotyping in Human Clinical Trials
Back to the list

April 7, 2025

Matt Clutter

You might also be interested by

Press Releases

CellCarta and Pillar Biosciences Announce Multi-Year Global Strategic Partnership to Expand Rapid, Decentralized Tumor Profiling for Oncology Clinical Trials

April 7, 2026

More info

News

CellCarta and Lunit Announce Strategic Collaboration to Accelerate AI-Enabled Digital Pathology for Companion Diagnostic Programs

March 30, 2026

More info

News

CellCarta Secures Global Exclusivity for Biofidelity's Aspyre® Lung to Advance Targeted Lung Cancer Testing

March 18, 2026

More info

Posters

Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

March 3, 2026

More info